Reply
- 1 May 2020
- journal article
- letter
- Published by Elsevier BV in Gastroenterology
- Vol. 158 (6), 1844
- https://doi.org/10.1053/j.gastro.2020.02.024
Abstract
No abstract availableFunding Information
- National Cancer Institute (R01 CA222900)
- National Institutes of Health
- AbbVie
This publication has 10 references indexed in Scilit:
- Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular CarcinomaGastroenterology, 2019
- Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular CarcinomaClinical Gastroenterology and Hepatology, 2019
- AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert ReviewGastroenterology, 2019
- Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort StudyGastroenterology, 2019
- Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United StatesClinical Gastroenterology and Hepatology, 2019
- Hepatocellular Carcinoma Surveillance: An Effective But Complex ProcessGastroenterology, 2019
- Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapyAlimentary Pharmacology & Therapeutics, 2018
- Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinomaJournal of Hepatology, 2017
- Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosisJournal of Hepatology, 2016
- Constructing Inverse Probability Weights for Marginal Structural ModelsAmerican Journal of Epidemiology, 2008